Skip to main content
SpringerLink
Log in

microRNA: A Potential Therapy Able to Target Multiple Cancer Pathways

  • Chapter
  • First Online:
Targeted Therapies

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 789 Accesses

Abstract

Cancer is a complex disease in which cells display uncontrollable growth and invade adjacent tissues, sometimes spreading to other locations in the body. Because of the complexity of tumors, they are often difficult to treat using conventional means such as radiation and chemotherapy. microRNAs (miRNAs) are a class of small noncoding RNAs that regulate the expression of several target proteins. They are involved in cellular processes such as proliferation, apoptosis, and differentiation, and are dysregulated in tumors and can function as tumor suppressors or oncogenes. In this chapter, we will discuss the role of miRNAs in cancer and potential miRNA-based therapeutic strategies in tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

    Article  PubMed  CAS  Google Scholar 

  2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.

    Article  PubMed  CAS  Google Scholar 

  3. Lee RC, Feinbaum RL. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.

    Article  PubMed  CAS  Google Scholar 

  4. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901–6.

    Article  PubMed  CAS  Google Scholar 

  5. Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86–9.

    Article  PubMed  CAS  Google Scholar 

  6. Berezikov E, van Tetering G, Verheul M, et al. Many novel mammalian microRNA candidates identified by extensive cloning and RAKE analysis. Genome Res. 2006;16(10):1289–98.

    Article  PubMed  CAS  Google Scholar 

  7. Berezikov E, Cuppen E, Plasterk RH. Approaches to microRNA discovery. Nat Genet. 2006;38(Suppl):S2–7.

    Article  PubMed  CAS  Google Scholar 

  8. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37(7):766–70.

    Article  PubMed  CAS  Google Scholar 

  9. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10A):1902–10.

    Article  PubMed  CAS  Google Scholar 

  10. Aravin AA, Lagos-Quintana M, Yalcin A, et al. The small RNA profile during Drosophila melanogaster development. Dev Cell. 2003;5(2):337–50.

    Article  PubMed  CAS  Google Scholar 

  11. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310(5755):1817–21.

    Article  PubMed  CAS  Google Scholar 

  12. Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68(10):3566–72.

    Article  PubMed  CAS  Google Scholar 

  13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  PubMed  CAS  Google Scholar 

  14. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60.

    Article  PubMed  CAS  Google Scholar 

  15. Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235–40.

    Article  PubMed  CAS  Google Scholar 

  16. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24):3011–6.

    Article  PubMed  CAS  Google Scholar 

  17. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297(5589):2056–60.

    Article  PubMed  CAS  Google Scholar 

  18. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001;15(20):2654–9.

    Article  PubMed  CAS  Google Scholar 

  19. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005;579(26):5822–9.

    Article  PubMed  CAS  Google Scholar 

  20. Martinez J, Tuschl T. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev. 2004;18(9):975–80.

    Article  PubMed  CAS  Google Scholar 

  21. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000;404(6775):293–6.

    Article  PubMed  CAS  Google Scholar 

  22. Lai EC, Tam B, Rubin GM. Pervasive regulation of Drosophila Notch target genes by GY-box-, Brd-box-, and K-box-class microRNAs. Genes Dev. 2005;19(9):1067–80.

    Article  PubMed  CAS  Google Scholar 

  23. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594–6.

    Article  PubMed  CAS  Google Scholar 

  24. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27(1):91–105.

    Article  PubMed  CAS  Google Scholar 

  25. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793–801.

    Article  PubMed  CAS  Google Scholar 

  26. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–9.

    Article  PubMed  CAS  Google Scholar 

  27. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005;33(17):5394–403.

    Article  PubMed  CAS  Google Scholar 

  28. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–47.

    Article  PubMed  CAS  Google Scholar 

  29. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol. 2007;27(12):4238–47.

    Article  PubMed  CAS  Google Scholar 

  30. Shell S, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA. 2007;104(27):11400–5.

    Article  PubMed  CAS  Google Scholar 

  31. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98.

    Article  PubMed  CAS  Google Scholar 

  32. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–6.

    Article  PubMed  CAS  Google Scholar 

  33. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48–57.

    Article  PubMed  CAS  Google Scholar 

  34. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67(20):9762–70.

    Article  PubMed  CAS  Google Scholar 

  35. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315(5818):1576–9.

    Article  PubMed  CAS  Google Scholar 

  36. Peng Y, Laser J, Shi G, et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res. 2008;6(4):663–73.

    Article  PubMed  CAS  Google Scholar 

  37. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21(9):1025–30.

    Article  PubMed  CAS  Google Scholar 

  38. Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69(19):7569–76.

    Article  PubMed  CAS  Google Scholar 

  39. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008;68(22):9125–30.

    Article  PubMed  CAS  Google Scholar 

  40. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.

    Article  PubMed  CAS  Google Scholar 

  41. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci. 2009;29:15161–18.

    Article  PubMed  CAS  Google Scholar 

  42. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828–33.

    Article  PubMed  CAS  Google Scholar 

  43. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64(9):3087–95.

    Article  PubMed  CAS  Google Scholar 

  44. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009;113(2):396–402.

    Article  PubMed  CAS  Google Scholar 

  45. Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377(1):114–9.

    Article  PubMed  CAS  Google Scholar 

  46. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283(44):29897–903.

    Article  PubMed  CAS  Google Scholar 

  47. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–34.

    Article  PubMed  CAS  Google Scholar 

  48. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–7.

    Article  PubMed  CAS  Google Scholar 

  49. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029–33.

    Article  PubMed  CAS  Google Scholar 

  50. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.

    Article  PubMed  CAS  Google Scholar 

  51. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282(19):14328–36.

    Article  PubMed  CAS  Google Scholar 

  52. Maehama T. PTEN: its deregulation and tumorigenesis. Biol Pharm Bull. 2007;30(9):1624–7.

    Article  PubMed  CAS  Google Scholar 

  53. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67(6):2456–68.

    Article  PubMed  CAS  Google Scholar 

  54. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459–65.

    Article  PubMed  CAS  Google Scholar 

  55. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2(10):764–76.

    Article  PubMed  CAS  Google Scholar 

  56. Schmidt EV. The role of c-myc in cellular growth control. Oncogene. 1999;18(19):2988–96.

    Article  PubMed  CAS  Google Scholar 

  57. Van de Casteele M, Kefas BA, Cai Y, et al. Prolonged culture in low glucose induces apoptosis of rat pancreatic beta-cells through induction of c-myc. Biochem Biophys Res Commun. 2003;312(4):937–44.

    Article  PubMed  Google Scholar 

  58. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008;14(8):2334–40.

    Article  PubMed  CAS  Google Scholar 

  59. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol. 2006;209(2):206–12.

    Article  PubMed  CAS  Google Scholar 

  60. Cui JG, Zhao Y, Sethi P, et al. Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. J Neurooncol. 2009;98:297–304.

    Article  PubMed  Google Scholar 

  61. Zhang Y, Chao T, Li R, et al. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med. 2009;87(1):43–51.

    Article  PubMed  CAS  Google Scholar 

  62. Kefas B, Comeau L, Floyd DH, et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci. 2009;29(48):15161–8.

    Article  PubMed  CAS  Google Scholar 

  63. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353–63.

    Article  PubMed  CAS  Google Scholar 

  64. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor – are we missing the mark? Lancet. 2003;362(9377):62–4.

    Article  PubMed  CAS  Google Scholar 

  65. Kojima K, Ohhashi R, Fujita Y, et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun. 2008;373(3):423–8.

    Article  PubMed  CAS  Google Scholar 

  66. Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010;79(6):817–24.

    Article  PubMed  CAS  Google Scholar 

  67. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–9.

    Article  PubMed  CAS  Google Scholar 

  68. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.

    Article  PubMed  CAS  Google Scholar 

  69. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76(5):582–8.

    Article  PubMed  CAS  Google Scholar 

  70. Legge F, Ferrandina G, Salutari V, Scambia G. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol. 2005;16 Suppl 4:iv95–101.

    Article  PubMed  Google Scholar 

  71. Mocellin S, Costa R, Nitti D. RNA interference: ready to silence cancer? J Mol Med. 2006;84(1):4–15.

    Article  PubMed  CAS  Google Scholar 

  72. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12(7):1179–87.

    Article  PubMed  CAS  Google Scholar 

  73. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441(7092):537–41.

    Article  PubMed  CAS  Google Scholar 

  74. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633–46.

    Article  PubMed  CAS  Google Scholar 

  75. Boutla A, Delidakis C, Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes. Nucleic Acids Res. 2003;31(17):4973–80.

    Article  PubMed  CAS  Google Scholar 

  76. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–9.

    Article  PubMed  Google Scholar 

  77. Czech MP. MicroRNAs as therapeutic targets. N Engl J Med. 2006;354(11):1194–5.

    Article  PubMed  CAS  Google Scholar 

  78. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006;34(8):2294–304.

    Article  PubMed  CAS  Google Scholar 

  79. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. PLoS Biol. 2004;2(4):E98.

    Article  PubMed  Google Scholar 

  80. Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther. 2008;117(1):94–104.

    Article  PubMed  CAS  Google Scholar 

  81. Bijsterbosch MK, Rump ET, De Vrueh RL, et al. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 2000;28(14):2717–25.

    Article  PubMed  CAS  Google Scholar 

  82. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem. 2004;279(17):17181–9.

    Article  PubMed  CAS  Google Scholar 

  83. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007;67(19):8994–9000.

    Article  PubMed  CAS  Google Scholar 

  84. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–803.

    Article  PubMed  CAS  Google Scholar 

  85. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27(15):2128–36.

    Article  PubMed  CAS  Google Scholar 

  86. Lankat-Buttgereit B, Goke R. Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy? Biol Cell. 2003;95(8):515–9.

    Article  PubMed  CAS  Google Scholar 

  87. Mudduluru G, Medved F, Grobholz R, et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007;110(8):1697–707.

    Article  PubMed  CAS  Google Scholar 

  88. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.

    Article  PubMed  CAS  Google Scholar 

  89. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle. 2008;7(16):2485–92.

    Article  PubMed  CAS  Google Scholar 

  90. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–52.

    Article  PubMed  CAS  Google Scholar 

  91. Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2009;18:181–7.

    Article  PubMed  Google Scholar 

  92. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008;7(6):759–64.

    Article  PubMed  CAS  Google Scholar 

  93. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 2008;105(10):3903–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Virginia, Charlottesville, VA, USA

    Benjamin W. Purow

Authors
  1. Benjamin Kefas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin W. Purow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin W. Purow .

Editor information

Editors and Affiliations

  1. Health System, Deptartment of Microbiology and Cancer C, University of Virginia, Charlottesville, 22908-0734, Virgin Islands, USA

    Daniel Gioeli

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kefas, B., Purow, B.W. (2011). microRNA: A Potential Therapy Able to Target Multiple Cancer Pathways. In: Gioeli, D. (eds) Targeted Therapies. Molecular and Translational Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-478-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-478-4_9

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-477-7

  • Online ISBN: 978-1-60761-478-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation